The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
Autor:
Griffin, Daniel O.
; Brennan-Rieder, Denise
; Ngo, Binh
; Kory, Pierre
; Confalonieri, Marco
; Shapiro, Leland
; Iglesias, Jose
; Dube, Michael
; Nanda, Neha
; In, Gino K.
; Arkfeld, Daniel
; Chaudhary, Preet
; Campese, Vito M.
; Hanna, Diana L.
; Sawcer, David
; Ehresmann, Glenn
; Peng, David
; Smorgorzewski, Miroslaw
; Amstrong, April
; Vinjevoll, Eivind H.
; Dasgupta, Rajkumar
; Sattler, Fred R.
; Mussini, Cristina
; Mitjà, Oriol
; Soriano, Vicente
; Peschanski, Nicolas
; Hayem, Gilles
; Piccirillo, Maria Carmela
; Lobo-Ferreira, António
; B. Rivero, Iraldo
; Hung, Ivan F. H.
; Rendell, Marc
; Ditmore, Stephen
; Varon, Joseph
; Marik, Paul
Fecha:
2021Palabra clave:
Revista / editorial:
AIDS reviewsTipo de Ítem:
Articulo Revista IndexadaDirección web:
https://www.aidsreviews.com/resumen.php?id=1567Resumen:
COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment of COVID-19 and advancing therapeutics is an appreciation of the multiple stages of this disease and the importance of timing for investigation and use of various agents. We considered articles related to COVID-19 indexed on PubMed published January 1, 2020-November 15, 2020, and considered papers on the medRxiv preprint server. We identified relevant stages of COVID-19 including three periods: pre-exposure, incubation, and detectable viral replication; and five phases: the viral symptom phase, the early inflammatory phase, the secondary infection phase, the multisystem inflammatory phase, and the tail phase. This common terminology should serve as a framework to guide when COVID-19 therapeutics being studied or currently in use is likely to provide benefit rather than harm.
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
36 |
104 |
92 |
111 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
The time to offer treatments for COVID-19
Ngo, Binh T.; Marik, Paul; Kory, Pierre; Shapiro, Leland; Thomadsen, Raphael; Iglesias, Jose; Ditmore, Stephen; Rendell, Marc; Varon, Joseph; Dube, Michael; Nanda, Neha; In, Gino K.; Arkfeld, Daniel; Chaudhary, Preet; Campese, Vito M.; Hanna, Diana L.; Sawcer, David E.; Ehresmann, Glenn; Peng, David; Smorgorzewski, Miroslaw; Armstrong, April; Dasgupta, Rajkumar; Sattler, Fred R.; Brennan-Rieder, Denise; Mussini, Cristina; Mitjà, Oriol; Soriano, Vicente ; Peschanski, Nicolas; Hayem, Gilles; Confalonieri, Marco; Piccirillo, Maria Carmela; Lobo-Ferreira, António; Bello Rivero, Iraldo; Turkia, Mika; Vinjevoll, Eivind H.; Griffin, Daniel O.; Hung, Ivan Fn (Expert opinion on investigational drugs, 2021)Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health ... -
Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study
Rodríguez-Toscano, Elisa; Alloza, Clara; Fraguas, David; Durán-Cutilla, Manuel; Roldán, Laura; Sánchez-Gutiérrez, Teresa; López-Montoya, Gonzalo; Parellada, Mara; Moreno, Carmen; Gayer-Anderson, Charlotte; E Jongsma, Hannah; Di Forti, Marta; Quattrone, Diego; Velthorst, Eva; de Haan, Lieuwe; Selten, Jean-Paul; Szöke, Andrei; Llorca, Pierre-Michel; Tortelli, Andrea; Bobes, Julio; Bernardo, Miguel; Sanjuán, Julio; Santos, José Luis; Arrojo, Manuel; Tarricone, Ilaria; Berardi, Domenico; Ruggeri, Mirella; Lasalvia, Antonio; Ferraro, Laura; La Cascia, Caterina; La Barbera, Daniele; Rossi Menezes, Paulo; Del-Ben, Cristina Marta; EU-GEI WP2 Group; Rutten, Bart P.; van Os, Jim; Jones, Peter B.; M. Murray, Robin; B. Kirkbride, James; Morgan, Craig; Díaz-Caneja, Covadonga M.; Arango, Celso (Schizophrenia Bulletin, 2023)Background: Use of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe ... -
The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study
Ferraro, Laura; La Cascia, Caterina; La Barbera, Daniele; Sánchez-Gutiérrez, Teresa ; Tripoli, Giada; Seminerio, Fabio; Sartorio, Crocettarachele; Sideli, Lucia; Arango, Celso; Arrojo, Manuel; Bernardo, Miguel; Bobes, Julio; Del-Ben, Cristina Marta; Gayer-Anderson, Charlotte; Jongsma, Hannah E.; Kirkbride, James B.; Lasalvia, Antonio; Tosato, Sarah; Llorca, Pierre-Michel; Menezes, Paulo Rossi; Rutten, Bart P.; Santos, Jose Luis; Sanjuán, Julio; Selten, Jean-Paul; Szöke, Andrei; Tarricone, Ilaria; Muratori, Roberto; Tortelli, Andrea; Velthorst, Eva; Rodriguez, Victoria; Quattrone, Andrea; Jones, Peter B.; Van Os, Jim; Vassos, Evangelos; Morgan, Craig; de Haan, Lieuwe; Reininghaus, Ulrich; Cardno, Alastair G.; Di Forti, Marta; Murray, Robin M.; Quattrone, Diego (Elsevier B.V., 2021)Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid ...